Immuneering Presented New Pancreatic Cancer Drug Data

The company shared findings on atebimetinib and its impact on patient survival at the 2026 AACR conference.

Updated on Sept. 28, 2026 in Cancer

Isometric editorial illustration of a glass beaker holding geometric crystalline shapes, representing medical research and pharmaceutical development. — Immuneering Corporation reported that its drug atebimetinib, combined with chemotherapy, helped pancreatic cancer patients preserve body mass and improved survival rates in clinical trials. AI Illustration. Upload story photo >

Live Poll

Do you believe recent advancements in cancer treatment are effectively improving long-term patient survival outcomes?

Immuneering Corporation unveiled clinical data suggesting that its drug, atebimetinib, helps preserve body mass in pancreatic cancer patients. Patients treated with the drug in combination with chemotherapy were significantly more likely to maintain or increase their weight.

Why it matters

Preserving body mass is a key factor in improving long-term outcomes for cancer patients, as weight stability correlates with increased survival. These results highlight a potential link between symptom management and extended life expectancy for those with pancreatic cancer.

In a study of 55 patients, 84% maintained or increased weight, with those gaining or keeping weight showing higher survival rates. Additionally, 66% of patients with baseline anorexia symptoms reported clinical improvement.

The players

Immuneering Corporation

This biotechnology company focuses on developing precision medicines for cancer and is based in New York.

The details

Researchers found that patients receiving atebimetinib alongside modified gemcitabine/nab-paclitaxel (mGnP) experienced improved anorexia symptoms and better body mass preservation. The analysis demonstrated that patients with stable or increased weight at the three-month mark survived significantly longer than those who lost weight.

April 24, 2026 was the data cutoff date for the Phase 2a study analysis.
September 28, 2026 was the date Immuneering presented the findings at the AACR conference.

Cancer
Sept. 25
Moleculin Biotech Presented Preclinical Annamycin Data
Cancer
Sept. 24
Sellas Life Sciences Shares Slipped Overnight
Cancer
Sept. 22
FDA Approved New Pancreatic Cancer Drug Daraxonrasib

Health Landscape

This development represents a shift toward addressing quality-of-life metrics alongside traditional tumor reduction in oncology trials. It builds upon the Phase 3 MAPKeeper 301 clinical trial, which seeks to validate these early survival signals in a broader patient population.

For patients and their families, these findings suggest that future treatment protocols may prioritize weight maintenance and symptom control to improve overall outcomes. Consult with your medical provider to determine if clinical trial participation or new treatment options are suitable for your specific health needs.

The takeaway

Maintaining physical health through weight stability remains a critical component in managing the progression of pancreatic cancer. These findings reinforce the importance of integrating nutritional and symptomatic care into standard cancer treatment plans.

What happens next

Immuneering Corporation is continuing the Phase 3 MAPKeeper 301 clinical trial, which will provide further data on the efficacy of the atebimetinib and mGnP combination therapy.